Skip to main content
. 2015 May 22;8(4):298–304. doi: 10.1111/cts.12275

Figure 3.

Figure 3

Sodium channel blockers mexiletine and prilocaine decrease DMPK mRNA in vivo. CD‐1 wild type mice were treated with daily IP injections of all three sodium channel blockers over a range of doses (6.25 mg/kg, 12.5 mg/kg, 25 mg/kg, or 50 mg/kg of mexiletine; 1.25 mg/kg, 2.5 mg/kg, and 5 mg/kg of prilocaine and 6.25 mg/kg, 12.5 mg/kg, or 25 mg/kg of procainamide) for 5 days. Control mice were treated with equal volume of vehicle. Gastrocnemius muscle was harvested for RT‐PCR. (A) Quantification of DMPK mRNA relative to β‐2‐microglobulin (the ratio of control group is set as 1) upon treatment with mexiletine. (B) Quantification of DMPK mRNA relative to β‐2‐microglobulin (the ratio of control group is set as 1) upon treatment with prilocaine. (C) Quantification of DMPK mRNA relative to β‐2‐microglobulin (the ratio of control group is set as 1) upon treatment with procainamide. Three mice per treatment group (control and treatment) were used. Mean ± SEM (bars) is shown. *p < 0.05, t‐test.